GlassScriptPhysician profile
Greg Eric Larsen
NPI 1578879441
$3,455.79
in general payments reported to CMS, 2019-2025
25 companies · $810 in 2025
The $810 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $440 · 2023: $849 · 2024: $1,011 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $560.03 | 2022-2025 | |
| Amgen INC. | $404.88 | 2021-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $340.31 | 2021-2025 | Lokelma, Farxiga, Evusheld |
| Otsuka America Pharmaceutical, INC. | $303.81 | 2021-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $239.15 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $225.45 | 2021-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $217.88 | 2021-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $153.30 | 2021-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $140.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $138.18 | 2021-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $112.29 | 2021-2023 | Krystexxa |
| Daiichi Sankyo INC. | $100.59 | 2022-2025 | Injectafer |
| Ani Pharmaceuticals, INC. | $76.16 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $72.92 | 2023-2024 | Korsuva, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.05 | 2021-2023 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $54.24 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $49.44 | 2023 | Gattex |
| Aurinia Pharma U.S., INC. | $47.87 | 2022-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $46.81 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.74 | 2025 | Empaveli |
| Lilly USA, LLC | $20.97 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $19.53 | 2023 | Oxlumo |
| Ascendis Pharma Endocrinology INC | $18.93 | 2025 | Yorvipath |
| Vifor Pharma, INC. | $18.89 | 2024 | Veltassa |
| Cormedix INC. | $15.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.